NBIX
Income statement / Annual
Last year (2025), Neurocrine Biosciences, Inc.'s total revenue was $2.86 B,
an increase of 21.45% from the previous year.
In 2025, Neurocrine Biosciences, Inc.'s net income was $478.60 M.
See Neurocrine Biosciences, Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2025
|
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
| Period Ended |
12/31/2025 |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
| Operating Revenue |
$2.86 B |
$2.36 B |
$1.89 B |
$1.49 B |
$1.13 B |
$1.05 B |
$788.10 M |
$451.20 M |
$161.63 M |
$15.00 M |
| Cost of Revenue |
$52.10 M
|
$34.00 M
|
$39.70 M
|
$23.20 M
|
$14.30 M
|
$10.10 M
|
$7.40 M
|
$4.90 M
|
$1.25 M
|
$0.00
|
| Gross Profit |
$2.81 B
|
$2.32 B
|
$1.85 B
|
$1.47 B
|
$1.12 B
|
$1.04 B
|
$780.70 M
|
$446.30 M
|
$160.37 M
|
$15.00 M
|
| Gross Profit Ratio |
0.98
|
0.99
|
0.98
|
0.98
|
0.99
|
0.99
|
0.99
|
0.99
|
0.99
|
1
|
| Research and Development Expenses |
$1.02 B
|
$731.10 M
|
$565.00 M
|
$463.80 M
|
$328.10 M
|
$275.00 M
|
$200.00 M
|
$155.80 M
|
$91.83 M
|
$94.29 M
|
| General & Administrative Expenses |
$0.00
|
$816.20 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$248.93 M
|
$169.91 M
|
$68.08 M
|
| Selling & Marketing Expenses |
$0.00
|
$191.00 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$1.16 B
|
$1.01 B
|
$887.60 M
|
$752.70 M
|
$583.30 M
|
$433.30 M
|
$354.10 M
|
$248.93 M
|
$169.91 M
|
$68.08 M
|
| Other Expenses |
$17.40 M
|
$12.50 M
|
$143.90 M
|
$0.00
|
$105.30 M
|
$164.50 M
|
$154.30 M
|
$4.80 M
|
$30.00 M
|
$0.00
|
| Operating Expenses |
$2.19 B
|
$1.75 B
|
$1.60 B
|
$1.22 B
|
$1.02 B
|
$872.80 M
|
$708.40 M
|
$409.50 M
|
$291.73 M
|
$162.37 M
|
| Cost And Expenses |
$2.24 B
|
$1.78 B
|
$1.64 B
|
$1.24 B
|
$1.03 B
|
$882.90 M
|
$715.80 M
|
$414.40 M
|
$292.99 M
|
$162.37 M
|
| Interest Income |
$90.30 M
|
$91.00 M
|
$0.00
|
$11.20 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$2.84 M
|
| Interest Expense |
$0.00
|
$126.60 M
|
$4.60 M
|
$7.10 M
|
$25.80 M
|
$32.80 M
|
$32.00 M
|
$30.53 M
|
$19.52 M
|
$0.00
|
| Depreciation & Amortization |
$30.10 M
|
$27.10 M
|
$21.30 M
|
$15.60 M
|
$10.90 M
|
$8.60 M
|
$7.45 M
|
$4.02 M
|
$2.40 M
|
$1.50 M
|
| EBITDA |
$666.60 M |
$639.70 M |
$416.10 M |
$264.60 M |
$138.10 M |
$148.10 M |
$85.90 M |
$56.30 M |
-$120.62 M |
-$139.64 M |
| EBITDA Ratio |
0.23
|
0.27
|
0.22
|
0.18
|
0.12
|
0.14
|
0.11
|
0.12
|
-0.75
|
-9.31
|
| Operating Income Ratio |
0.22
|
0.24
|
0.13
|
0.17
|
0.09
|
0.16
|
0.09
|
0.08
|
-0.81
|
-9.82
|
| Total Other Income/Expenses Net |
$86.30 M
|
-$84.50 M
|
$81.20 M
|
-$35.10 M
|
-$1.10 M
|
-$56.30 M
|
-$25.80 M
|
-$15.05 M
|
-$11.18 M
|
$6.28 M
|
| Income Before Tax |
$705.40 M
|
$486.00 M
|
$332.10 M
|
$213.90 M
|
$101.40 M
|
$106.70 M
|
$46.50 M
|
$21.84 M
|
-$142.54 M
|
-$141.09 M
|
| Income Before Tax Ratio |
0.25
|
0.21
|
0.18
|
0.14
|
0.09
|
0.1
|
0.06
|
0.05
|
-0.88
|
-9.41
|
| Income Tax Expense |
$226.80 M
|
$144.70 M
|
$82.40 M
|
$59.40 M
|
$11.80 M
|
-$300.60 M
|
$9.50 M
|
$730.00 K
|
$0.00
|
$0.00
|
| Net Income |
$478.60 M
|
$341.30 M
|
$249.70 M
|
$154.50 M
|
$89.60 M
|
$407.30 M
|
$37.00 M
|
$21.11 M
|
-$142.54 M
|
-$141.09 M
|
| Net Income Ratio |
0.17
|
0.14
|
0.13
|
0.1
|
0.08
|
0.39
|
0.05
|
0.05
|
-0.88
|
-9.41
|
| EPS |
4.81 |
3.4 |
2.56 |
1.61 |
0.95 |
4.37 |
0.4 |
0.22 |
-1.62 |
-1.63 |
| EPS Diluted |
4.67 |
3.29 |
2.47 |
1.56 |
0.92 |
4.16 |
0.39 |
0.22 |
-1.62 |
-1.63 |
| Weighted Average Shares Out |
$99.50 M
|
$100.40 M
|
$97.70 M
|
$95.80 M
|
$94.60 M
|
$93.10 M
|
$91.63 M
|
$95.40 M
|
$87.99 M
|
$86.56 M
|
| Weighted Average Shares Out Diluted |
$102.50 M
|
$103.70 M
|
$101.00 M
|
$98.90 M
|
$97.90 M
|
$97.80 M
|
$95.73 M
|
$95.40 M
|
$88.09 M
|
$86.71 M
|
| Link |
|
|
|
|
|
|
|
|
|
|
